| Literature DB >> 21291592 |
Alan R Katz1, Arlene E Buchholz, Kialani Hinson, Sarah Y Park, Paul V Effler.
Abstract
Although infrequently diagnosed in the United States, leptospirosis is a notable reemerging infectious disease throughout developing countries. Until 1995, when the disease was eliminated from the US list of nationally notifiable diseases, Hawaii led the nation in reported annual incidence rates. Leptospirosis remains a notifiable disease in Hawaii. To ascertain the status of leptospirosis in Hawaii since the most recent US report in 2002, we reviewed 1999-2008 data obtained from case investigation reports by the Hawaii State Department of Health. Of the 345 case reports related to in-state exposures, 198 (57%) were laboratory confirmed. Our findings indicate a change in seasonal disease occurrence from summer to winter and in the infective serogroup from Icterohemorrhagiae to Australis. Also, during the past 20 years, recreational exposures have plateaued, while occupational exposures have increased. Ongoing surveillance is needed to clarify and track the dynamic epidemiology of this widespread zoonosis.Entities:
Mesh:
Year: 2011 PMID: 21291592 PMCID: PMC3204774 DOI: 10.3201/eid1702.101109
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Month of onset for 198 laboratory-confirmed leptospirosis cases, Hawaii, USA, 1999–2008.
Sex, age, and island of exposure for 198 case-patients with laboratory-confirmed leptospirosis, Hawaii, USA, 1999–2008
| Variable | No. (%) case-patients | Estimated mean annual incidence rate* |
|---|---|---|
| Sex | ||
| M | 181 (91) | 2.97 |
| F | 17 (9) | 0.28 |
| Age group, y | ||
| 0–9 | 1 (1) | 0.06 |
| 10–19 | 24 (12) | 1.46 |
| 20–29 | 48 (24) | 2.87 |
| 30–39 | 31 (16) | 1.69 |
| 40–49 | 38 (19) | 2.05 |
| 50–59 | 36 (18) | 2.55 |
| 60–69 | 15 (8) | 1.68 |
| 70–79 | 5 (3) | 0.64 |
| Island | ||
| Hawaii | 98 (49) | 6.59 |
| Kauai | 47 (24) | 8.06 |
| Oahu | 44 (23) | 0.50 |
| Maui | 4 (2) | 0.34 |
| Molokai | 1 (1) | 1.38 |
| Unknown | 4 (2) |
*No. cases/100,000 population. Rate = no. case-patients observed over 10 years for the specified category divided by 10 divided by specified subgroup population estimate from 2000 US Census data ().
Figure 2Exposure locations associated with the greatest number of leptospirosis cases, Hawaii, USA, 1999–2008.
Figure 3Trends in exposure classification for laboratory-confirmed leptospirosis cases, Hawaii, USA, 1989–2008.
Clinical findings for 198 case-patients with laboratory-confirmed leptospirosis, Hawaii, USA, 1999–2008
| Sign, symptoms, and laboratory result | No. (%) patients affected | No. patients with data available |
| Sign or symptom | ||
| Fever | 187 (98) | 191 |
| Myalgia | 162 (88) | 185 |
| Headache | 156 (87) | 179 |
| Nausea | 117 (68) | 173 |
| Vomiting | 101 (59) | 172 |
| Arthralgia | 73 (46) | 157 |
| Diarrhea | 79 (46) | 171 |
| Backache | 50 (34) | 146 |
| Jaundice | 53 (33) | 163 |
| Oliguria or anuria | 32 (21) | 152 |
| Conjunctival suffusion | 30 (19) | 156 |
| Nuchal rigidity | 23 (14) | 159 |
| Pneumonia | 13 (8) | 154 |
| Hepatosplenomegaly | 8 (6) | 140 |
| Laboratory results | ||
| Renal | ||
| Hematuria | 78 (73) | 107 |
| Proteinuria | 71 (68) | 105 |
| Elevated creatinine (>1.5 mg/dL) | 60 (51) | 118 |
| Elevated blood urea nitrogen (>20 mg/dL) | 68 (50) | 136 |
| Hepatic | ||
| Elevated alanine aminotransferase (>40 U/L) | 109 (74) | 147 |
| Elevated total bilirubin (>1 mg/dL) | 85 (63) | 134 |
| Hematologic | ||
| Thrombocytopenia (<140 × 109/L) | 97 (66) | 146 |
| Elevated leukocyte count (>10 × 109 cells/L) | 74 (48) | 155 |
| Decreased hematocrit (<34%) | 56 (38) | 146 |